- Home
- WWW vs ARQT Comparison
WWW vs ARQT Comparison
Compare WWW & ARQT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WWW
- ARQT
- Stock Information
- Founded
- WWW 1883
- ARQT 2016
- Country
- WWW United States
- ARQT United States
- Employees
- WWW N/A
- ARQT N/A
- Industry
- WWW Shoe Manufacturing
- ARQT Biotechnology: Pharmaceutical Preparations
- Sector
- WWW Consumer Discretionary
- ARQT Health Care
- Exchange
- WWW Nasdaq
- ARQT Nasdaq
- Market Cap
- WWW 2.5B
- ARQT 2.1B
- IPO Year
- WWW N/A
- ARQT 2020
- Fundamental
- Price
- WWW $24.84
- ARQT $20.74
- Analyst Decision
- WWW Buy
- ARQT Strong Buy
- Analyst Count
- WWW 6
- ARQT 7
- Target Price
- WWW $29.67
- ARQT $19.00
- AVG Volume (30 Days)
- WWW 1.8M
- ARQT 1.9M
- Earning Date
- WWW 11-06-2025
- ARQT 10-28-2025
- Dividend Yield
- WWW 1.59%
- ARQT N/A
- EPS Growth
- WWW N/A
- ARQT N/A
- EPS
- WWW 1.04
- ARQT N/A
- Revenue
- WWW $1,821,400,000.00
- ARQT $263,464,999.00
- Revenue This Year
- WWW $7.52
- ARQT $72.46
- Revenue Next Year
- WWW $6.57
- ARQT $31.69
- P/E Ratio
- WWW $24.15
- ARQT N/A
- Revenue Growth
- WWW N/A
- ARQT 99.50
- 52 Week Low
- WWW $9.58
- ARQT $8.03
- 52 Week High
- WWW $32.80
- ARQT $21.30
- Technical
- Relative Strength Index (RSI)
- WWW 28.04
- ARQT 68.31
- Support Level
- WWW $24.58
- ARQT $16.68
- Resistance Level
- WWW $28.68
- ARQT $21.30
- Average True Range (ATR)
- WWW 1.00
- ARQT 1.00
- MACD
- WWW -0.65
- ARQT 0.25
- Stochastic Oscillator
- WWW 7.28
- ARQT 89.84
About WWW Wolverine World Wide Inc.
Wolverine World Wide Inc is engaged in designing, manufacturing, sourcing, marketing, licensing, and distributing branded footwear, apparel, and accessories. The company's segment includes Active Group; Work Group; Corporate and Other. It generates maximum revenue from the Active Group segment. Active Group segment consists of Merrell footwear and apparel, Saucony footwear and apparel, Sweaty Betty activewear, and Chaco footwear.
About ARQT Arcutis Biotherapeutics Inc.
Arcutis Biotherapeutics Inc is a medical dermatology company. It is developing treatments for patients with immune-mediated dermatological diseases and conditions. It is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targets to solve persistent treatment challenges in serious diseases of the skin. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population.